First and only drug releasing system to provide extended local delivery of a cancer medication into the bladder, with 82 percent of patients achieving complete response without the need for ...

Purpose: To determine maximum-tolerated dose, toxicities, and pharmacokinetics associated with weekly intravesical gemcitabine therapy in patients with superficial bladder cancer. Patients and Methods ...

Eligible patients underwent maximal transurethral resection of their bladder tumors followed by twice-weekly infusion of gemcitabine with 2 Gy/d concurrent radiotherapy to the bladder, for a total of ...

Credit: J&J. The New Drug Application is supported by data from cohort 2 of the single-arm, phase 2b SunRISe-1 study. The device remains in the bladder and provides a sustained release of gemcitabine ...

Relmada Therapeutics announced a licensing agreement for NDV-01, a new treatment for non-muscle invasive bladder cancer. Phase 2 data expected in April 2025. Relmada Therapeutics, Inc. has announced ...

The device remains in the bladder and provides a sustained release of gemcitabine throughout the day. The Food and Drug Administration (FDA) has granted Priority Review to TAR-200 for the treatment of ...

Please provide your email address to receive an email when new articles are posted on . Gemcitabine and docetaxel conferred a numerically superior RFS rate than BCG at every time point evaluated.

Credit: Johnson & Johnson. Inlexzo is supplied as a single-dose intravesical system containing 225mg of gemcitabine plus a sterile urinary catheter and stylet. Inlexzo is an intravesical gemcitabine ...

The pretzel-shaped gemcitabine intravesical system (formerly TAR-200) yields a high DFS rate among patients with papillary disease-only NMIBC -- including T1 – that fails to respond to BCG. The ...

Patients with locally advanced muscle-invasive bladder cancer may benefit from dose-dense gemcitabine and cisplatin. The treatment of preoperative dose-dense gemcitabine and cisplatin chemotherapies ...

Less than two months after receiving priority review status for an NDA, Johnson & Johnson won U.S. FDA approval of Inlexzo, its intravesical gemcitabine releasing system previously known as TAR-200, ...